Last edition
News about Global Pharma
Gerresheimer Expands Capacities for Medical Systems in USA
Gerresheimer is significantly expanding its production capacities for medical systems such as inhalers and autoinjectors in the United States.
Global Pharma | 28/05/2024 | By Manvi | 388
AcariaHealth Opens Modern Specialty Pharmacy Facility in Chesterfield, Missouri
The facility is the home of Foundation Care, one of AcariaHealth's Centers of Excellence devoted to providing personalized care to patients with rare and chronic conditions.
Global Pharma | 28/05/2024 | By Manvi | 428
Novartis Presents Interim Analysis of atrasentan Phase III Data
Novartis has presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN).
Global Pharma | 28/05/2024 | By Aishwarya | 811
Biocon Signs Exclusive Deal for Commercializing Liraglutide in South Korea with Handok
Biocon Ltd. has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.
Global Pharma | 28/05/2024 | By Aishwarya | 893
US FDA Grants Priority Review to Sarclisa for Treatment of Transplant-Ineligible NDMM
Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for the investigational use of Sarclisa (isatuximab).
Global Pharma | 28/05/2024 | By Aishwarya | 835
This expansion will enhance Lilly's capacity to manufacture active pharmaceutical ingredients (API) for Zepbound® (tirzepatide) injection and Mounjaro® (tirzepatide) injection so that more adults with chronic diseases like obesity and type 2 diabetes may benefit from these important treatments.
Global Pharma | 27/05/2024 | By Manvi | 1352
SystImmune Appoints Dr. Jonathan Cheng as New Chief Medical Officer
He joined SystImmune from Bristol Myers Squibb, where he served as the Senior Vice President and Therapeutic Area Oncology Head, overseeing late-stage clinical development of the oncology portfolio. Dr. Cheng succeeds Dr. Martin Olivo, who is leaving SystImmune to pursue external opportunities.
Global Pharma | 27/05/2024 | By Manvi | 948
Orna Therapeutics Acquires ReNAgade to Strengthen Expertise in RNA Therapies
Orna Therapeutics has recently acquired ReNAgade Therapeutics, a pioneer in unlocking the potential of RNA therapeutics that demonstrated industry-leading delivery to multiple extra-hepatic cells in non-human primate (NHP) models over the past 18 months.
Global Pharma | 27/05/2024 | By Aishwarya | 323
Merck Signs Definitive Deal to Acquire Mirus Bio for USD 600 Million
Merck has signed a definitive agreement to acquire Mirus Bio for USD 600 million.
Global Pharma | 27/05/2024 | By Aishwarya | 667
Global Group Introduces Innovative Salivary Testing Pilot to Combat Oral Health Disparities
Global Group, Inc., in a strategic alliance with technology partner Oral Genome, announce an innovative program aimed at tackling global oral health disparities.
Global Pharma | 24/05/2024 | By Manvi | 441
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy